REGISTER
Roy S. Herbst | Is Standard Chemo Still the Best We Can Do for Lung Cancer?
Dr. Herbst discusses how the alpha-bias mechanism aims to sustain meaningful immune activation while avoiding the systemic toxicity that previously limited cytokine therapy, and what a positive MarsLight-11 result would mean for the future of docetaxel as a benchmark in this setting.

Roy S. Herbst, MD, PhD, Yale Cancer Center, USA

For patients with advanced squamous NSCLC who have progressed on both chemotherapy and immune checkpoint inhibitors, no reliable later-line standard of care exists. IBI363, a PD-1/IL-2 alpha-biased bispecific antibody fusion protein, is being tested in the MarsLight-11 phase 3 trial as a potential answer to this gap. Dr. Herbst discusses how the alpha-bias mechanism aims to sustain meaningful immune activation while avoiding the systemic toxicity that previously limited cytokine therapy, and what a positive MarsLight-11 result would mean for the future of docetaxel as a benchmark in this setting.

0
0
Loading